Stanford SPARK translational program
A nanoparticle antibiotic adjuvant that has the ability to target persister cells in biofilms of chronic bacterial infections and reverse the resistance of multi-resistant bacteria to commonly used antibiotics. Excellent in vitro and in vivo efficacy against multiple bacterial species and on going safety and toxicology show an excellent safety profile.
A nanoparticle antibiotic adjuvant that has the ability to target persister cells in biofilms of chronic bacterial infections and reverse the resistance of multi-resistant bacteria to commonly used antibiotics. Excellent in vitro and in vivo efficacy against multiple bacterial species and on going safety and toxicology show an excellent safety profile.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
Antibiotic adjuvant for chronic bacterial infections
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
